Prevalence of and Associated Factors for Eyelid Cancer in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)

被引:12
|
作者
Bas, Zeynep [1 ]
Sharpe, James [2 ]
Yaghy, Antonio [1 ]
Zhang, Qiang [2 ]
Shields, Carol L. [1 ]
Hyman, Leslie [2 ,3 ,4 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Hosp, Ocular Oncol Serv, Philadelphia, PA USA
[2] Thomas Jefferson Univ, Wills Eye Hosp, Vickie & Jack Farber Vis Res Ctr, Philadelphia, PA USA
[3] Thomas Jefferson Univ, Wills Eye Hosp, Vickie & Jack Farber Vis Res Ctr, 840 Walnut St,Suite 1530, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Wills Eye Hosp, Vickie & Jack Farber Vis Res Ctr, 840 Walnut St,Suite 1530, Philadelphia, PA 19107 USA
来源
OPHTHALMOLOGY SCIENCE | 2023年 / 3卷 / 01期
关键词
Basal cell carcinoma; IRIS Registry; Malignant melanoma; Smoking; Squamous cell carcinoma; BASAL-CELL CARCINOMA; SKIN-CANCER; CLINICOPATHOLOGICAL FEATURES; MALIGNANT-TUMORS; SMOKING; INDIA;
D O I
10.1016/j.xops.2022.100227
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To estimate the prevalence of eyelid cancers in the American Academy of Ophthalmology IRIS (R) Registry (Intelligent Research in Sight) and evaluate the associated factors. Design: Retrospective IRIS Registry database study. Participants: All patients in the IRIS Registry between December 1, 2010, and December 1, 2018, with International Classification of Disease, ninth and 10th revisions, codes for eyelid cancers (basal cell carcinoma [BCC], squamous cell carcinoma [SCC], malignant melanoma [MM], sebaceous carcinoma/other specified malignant neoplasm [SBC], melanoma in situ [MIS], and unspecified malignant neoplasm [UMN]). Methods: The prevalence of each eyelid cancer type was estimated overall and by age group, sex, race, ethnicity, and smoking status. The associations between any eyelid cancer (AEC) or each cancer type and possible risk factors were examined using univariate and multivariate logistic regression models. Main Outcome Measures: Prevalence of and associated factors for each eyelid cancer type. Results: There were 82 136 patients with eyelid cancer identified. The prevalence of AEC was 145.1 per 100 000 population. The cancer-specific prevalence ranged from 87.9 (BCC) to 25.6 (UMN), 11.1 (SCC), 5.0 (SBC), 4.1 (MM), and 0.4 (MIS) per 100 000 population. The prevalence of AEC and each cancer type increased with increasing age (all P < 0.0001), and the prevalence of AEC, BCC, SCC, and MM was higher in males (all P < 0.0001), MIS (P = 0.02). The prevalence of BCC, SCC, MM, SBC, and AEC was highest in Whites versus that in patients of any other race (all P < 0.0001). In the multivariate logistic regression model with associated risk factors (age, sex, race, ethnicity, and smoking status), AEC was associated with older age groups ([< 20 years reference {ref.}]; odds ratio [95% confidence interval]: 20-39 years: 3.35 [1.96-5.72]; 40-65 years: 24.21 [14.80-39.59]; and > 65 years: 42.78 [26.18-69.90]), male sex (female [ref.]; 1.40 [1.33-1.48]), White race (inverse associations with African Americans [0.12 {0.09-0.16}], Asians [0.19 {0.13-0.26}], others [0.59 {0.40-0.89}]), and ethnicity (non-Hispanic [ref.]; Hispanic: 0.38 [0.33-0.45]; unknown: 0.81 [0.75-0.88]). Active smoking (never smoker [ref.]) was associated with AEC (1.11 [1.01-1.21]), BCC (1.27 [1.23-1.31]), SCC (1.59 [1.46-1.73]), and MM (1.26 [1.08-1.46]). Conclusions: This study reports the overall and cancer- specific prevalence of eyelid cancers using a large national clinical eye disease database. Smoking was found to be associated with AEC, BCC, SCC, and MM, which is a new observation. This epidemiologic profile of on-eyelid cancers is valuable for identifying patients at a higher risk of malignancy, allocating medical resources, and improving cancer care. (c) 2022 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [31] IMPUTATION OF DISEASE SEVERITY FOR DIABETIC RETINOPATHY CLINICAL ENCOUNTERS IN THE IRIS® REGISTRY (INTELLIGENT RESEARCH IN SIGHT)
    Chapman, R.
    Nguyen, T.
    Hatfield, M.
    Leng, T.
    Mbagwu, M.
    Torres, A.
    Borkar, D.
    VALUE IN HEALTH, 2023, 26 (06) : S386 - S386
  • [32] Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry
    Sun, Michel M.
    Kelly, Scott P.
    Mylavarapu, Apoorva L.
    Holland, Gary N.
    Coleman, Anne L.
    Yu, Fei
    Hsu, Stephen
    Lum, Flora
    Gordon, Lynn K.
    OPHTHALMOLOGY, 2021, 128 (06) : 910 - 919
  • [33] Association of Environmental Factors with Neovascular Age-Related Macular Degeneration (nvAMD) using the Intelligent Research in Sight (IRIS)® Registry
    Hunt, Matthew
    Saraf, Steven
    Chee, Yewlin
    Wu, Yue
    Lee, Cecilia
    Lee, Aaron
    Manookin, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [34] Incidence and Risk Factors for Retinal Detachment and Retinal Tear after Cataract Surgery IRIS® Registry (Intelligent Research in Sight) Analysis
    Morano, Michael J.
    Khan, M. Ali
    Zhang, Qiang
    Halfpenny, Colleen P.
    Wisner, Douglas M.
    Sharpe, James
    Li, Alexander
    Tomaiuolo, Maurizio
    Haller, Julia A.
    Hyman, Leslie
    Ho, Allen C.
    OPHTHALMOLOGY SCIENCE, 2023, 3 (04):
  • [35] Sociodemographic Patterns in Keratoconus Treatment (2015-2020): IRIS® Registry (Intelligent Research in Sight) Analysis
    Hyman, Leslie
    Syed, Zeba
    Tomaiuolo, Maurizio
    Zhang, Qiang
    Prajna, Venkatesh
    Rapuano, Christopher
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [36] The epidemiology of pediatric dry eye disease in the United States: An IRIS® registry (Intelligent Research in Sight) analysis
    Douglas, Vivian Paraskevi
    Hall, Nathan
    Ross, Connor
    Douglas, Konstantinos A. A.
    Elze, Tobias
    Miller, Joan W.
    Lorch, Alice C.
    Traish, Aisha S.
    OCULAR SURFACE, 2024, 32 : 106 - 111
  • [37] Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
    Kopplin, Laura
    Armbrust, Karen
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4164 - 4165
  • [38] Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS® Registry (Intelligent Research in Sight)
    Mishra, Kapil
    Brant, Arthur
    Pershing, Suzann
    Perlroth, Ashton Tristan
    Bair, Henry
    Xu, Christine
    Do, Diana V.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [39] The impact of month and season on the incidence of giant cell arteritis: an Intelligent Research in Sight (IRIS) Registry analysis
    Wladis, Edward J.
    Ata, Ashar
    Li, Charles
    Peng, Xuan
    Waxman, Michael J.
    Pauze, Denis R.
    Lum, Flora
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (02) : 609 - 614
  • [40] The impact of month and season on the incidence of giant cell arteritis: an Intelligent Research in Sight (IRIS) Registry analysis
    Edward J. Wladis
    Ashar Ata
    Charles Li
    Xuan Peng
    Michael J. Waxman
    Denis R. Pauze
    Flora Lum
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 (2) : 609 - 614